FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Solit

Research Profile

Chemicals & Drugs

Anatomy

Tumor Cell Line

Physiology

Living Beings

Disorders

Neoplasms

Co-author Network

Publications

TOP 3
Federica Catalanotti; Michael F Berger; Richard D Carvajal; Tunc Iyriboz; Mario E Lacouture; Katherine S Panageas; Melissa P Pulitzer; Neal Rosen; Gary K Schwartz; Sasinya N Scott; David B Solit; Jedd D Wolchok; Paul B Chapman
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.
Yufang Wang; Adam J Bass; James M Bugni; Gerald C Chu; Channing J Der; Jessica Gierut; Shouyong Peng; Mark Philips; David B Solit; Efsevia Vakiani; Sérgia Velho; Kevin M Haigis
Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression.
Gil Redelman-Sidi; David B Solit; Gopa Iyer; Michael S Glickman
Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Solit (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Federica Catalanotti; Michael F Berger; Richard D Carvajal; Tunc Iyriboz; Mario E Lacouture; Katherine S Panageas; Melissa P Pulitzer; Neal Rosen; Gary K Schwartz; Sasinya N Scott; David B Solit; Jedd D Wolchok; Paul B Chapman
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(8):2257-64.
2013: Yufang Wang; Adam J Bass; James M Bugni; Gerald C Chu; Channing J Der; Jessica Gierut; Shouyong Peng; Mark Philips; David B Solit; Efsevia Vakiani; Sérgia Velho; Kevin M Haigis
Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression.
Cancer discovery 2013;3(3):294-307.
2013: Gil Redelman-Sidi; David B Solit; Gopa Iyer; Michael S Glickman
Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells.
Cancer research 2013;73(3):1156-67.
2013: Rachel N Grisham; David M Hyman; Alexia Iasonos; Gopa Iyer; Douglas A Levine; Carol Aghajanian; Michael F Berger; Fanny Dao; Deborah DeLair; Karuna Garg; David R Spriggs; Qin Zhou; David B Solit
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Cancer 2013;119(3):548-54.
2012: Margaret K Callahan; Omar Abdel-Wahab; Young Rock Chung; James J Harding; Virginia M Klimek; Ross L Levine; Taha Merghoub; Raajit Rampal; Neal Rosen; David B Solit; Jedd D Wolchok; Paul B Chapman
Progression of RAS-mutant leukemia during RAF inhibitor treatment.
The New England journal of medicine 2012;367(24):2316-21.
2012: Sam S Chang; Philipp Dahm; Colin P N Dinney; S Machele Donat; Felix Y Feng; John L Gore; Donna Hansel; Yair Lotan; Peter H O'Donnell; Dipen J Parekh; David B Solit; Matthew I Milowsky
12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report.
Urologic oncology 2012;30(6):944-7.
2012: Gopa Iyer; Manickam Janakiraman; Matthew I Milowsky; Irina Ostrovnaya; Luke Peng; Mono Pirun; Chris Sander; Sasinya N Scott; Nicholas D Socci; Hikmat Al-Ahmadie; Dean F Bajorin; Michael F Berger; Bernard H Bochner; Timothy Chan; Aphrothiti J Hanrahan; Adriana Heguy; Barry S Taylor; Agnes Viale; David B Solit
Genome sequencing identifies a basis for everolimus sensitivity.
Science (New York, N.Y.) 2012;338(6104):221.
2012: Diane L Reidy-Lagunes; Marinela Capanu; Ellen M Hollywood; M Catherine Pietanza; Michal F Segal; David B Solit; Laura H Tang; Efsevia Vakiani; Leonard B Saltz
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
Cancer 2012;118(19):4795-800.
2012: Kimberly Brown Dahlman; John A Glaspy; Donna J Hicks; Donald Hucks; Katherine Hutchinson; Peilin Jia; Pamela L Lyle; James L Netterville; Charles Ng; Antoni Ribas; Neal Rosen; David B Solit; Jeffrey A Sosman; Zengliu Su; Cindy L Vnencak-Jones; Junfeng Xia; Zhongming Zhao; Mohammad Atefi; Viviana Bozon; Suzanne Branch; William Pao
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
Cancer discovery 2012;2(9):791-7.
2012: Efsevia Vakiani; Agnes Viale; Martin Weiser; Zhaoshi Zeng; Andrea Cercek Hanjis; Timothy Chan; Michael D'Angelica; Adriana Heguy; Manickam Janakiraman; Nancy Kemeny; Philip Paty; Leonard B Saltz; Ronglai Shen; Jinru Shia; Rileen Sinha; David B Solit
Comparative genomic analysis of primary versus metastatic colorectal carcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(24):2956-62.
2012: Aphrothiti J Hanrahan; David B Solit
RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas.
Cancer discovery 2012;2(8):666-9.
2012: Eric A Sherer; David B Solit; Chandra P Belani; Merrill J Egorin; Percy S Ivy; Jeffrey A Lieberman; Stephen B Manuck; Stephen R Marder; Matthew F Muldoon; Bruce G Pollock; Mark E Sale; Howard I Scher; Robert R Bies
Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.
Journal of pharmacokinetics and pharmacodynamics 2012;39(4):393-414.
2012: Ravid Straussman; Jennifer A Wargo; Michal Barzily-Rokni; Paul B Chapman; Zachary A Cooper; Ashli Davis; Jinyan Du; Keith T Flaherty; Dennie T Frederick; Joshua Gould; Roger S Lo; Margaret M Mongare; Teppei Morikawa; Shuji Ogino; Zhi Rong Qian; Antoni Ribas; Kevin Shee; David B Solit; Todd R Golub
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Nature 2012;487(7408):500-4.
2012: Abdulateef O Aregbe; Chandra P Belani; Merrill J Egorin; Percy S Ivy; Suresh Ramalingam; Ramesh K Ramanathan; Howard I Scher; Eric A Sherer; David B Solit; Robert R Bies
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.
Cancer chemotherapy and pharmacology 2012;70(1):201-5.
2012: Sandra Misale; Andrea Sartore-Bianchi; Elisa Scala; Roberta Schiavo; Salvatore Siena; Giulia Siravegna; David B Solit; Efsevia Vakiani; Emanuele Valtorta; Silvio Veronese; Martin Weiser; Rona Yaeger; Carlo Zanon; Katia Bencardino; Valentina Boscaro; Michela Buscarino; Andrea Cercek; Chin-Tung Chen; Federica Di Nicolantonio; Margherita Gallicchio; Marcello Gambacorta; Sebastijan Hobor; Manickam Janakiraman; David Liska; Enzo Medico; Alberto Bardelli
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Nature 2012;486(7404):532-6.
2012: Leonard Saltz; Amy Scales; David B Solit; Laurence K Tokaz; Efsevia Vakiani; Feng Zhan; Paul R Conkling; Shaker Dakhil; W Graydon Harker; Mark A O'Rourke; Diane Lauren Reidy; Donald A Richards; Lina Asmar; Suprith Badarinath; David Barrera; Bryan Bienvenu; George Birchfield; Kristi A Boehm; Marinella Capanu; Allen Cohn
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
Clinical colorectal cancer 2012;11(2):101-11.
2012: Federica Catalanotti; David B Solit
Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(9):2420-2.
2012: Gopa Iyer; Steven M Larson; Michael J Morris; Dana Elizabeth Rathkopf; Neal Rosen; Howard I Scher; Lawrence H Schwartz; Susan F Slovin; Tracy Curley; Anthony Delacruz; Merrill J Egorin; Glenn Heller; S Percy Ivy; Macaulay Steers; Qing Ye; David B Solit
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Cancer chemotherapy and pharmacology 2012;69(4):1089-97.
2012: David B Solit; Pasi A Janne
Translational medicine: Primed for resistance.
Nature 2012;483(7387):44-5.
2012: Mikhail Doubrovin; Ronald Finn; Tatiana Kochetkova; Ekaterina Moroz; Nagavarakishore Pillarsetti; Neal Rosen; Inna Serganova; David B Solit; Lyudmila Ageyeva; Jian T Che; Ronald G Blasberg
Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imaging.
Molecular imaging 2012;11(1):67-76.
2012: F Xing; B S Taylor; Agnes Viale; J Wolchok; G Bollag; D Cobrinik; Elisa de Stanchina; I Dolgalev; Humilidad F Gallardo; B Hefter; Adriana Heguy; Alan N Houghton; M Janakiraman; C Liu; Taha Merghoub; Y Persaud; Christine A Pratilas; Qing-Bai She; David B Solit
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Oncogene 2012;31(4):446-57.
2012: Mario Lacouture; Kathryn O'Reilly; Neal Rosen; David B Solit
Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(3):329-30.
2012: Aphrothiti J Hanrahan; Adriana Heguy; Manickam Janikariman; Tari A King; Douglas A Levine; Narciso Olvera; Neal Rosen; Rita A Sakr; Chris Sander; Stefano Scarperi; Nikolaus Schultz; Qing-Bai She; David R Spriggs; Elisa de Stanchina; Ellen V Stevens; Barry S Taylor; Maggie L Westfal; Manickam Janakiraman; Carol Aghajanian; Dilip D Giri; David B Solit
Genomic complexity and AKT dependence in serous ovarian cancer.
Cancer discovery 2012;2(1):56-67.
2012: Christine A Pratilas; Feng Xing; David B Solit
Targeting oncogenic BRAF in human cancer.
Current topics in microbiology and immunology 2012;355():83-98.
2011: Moriah H Nissan; David B Solit
The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?
Current oncology reports 2011;13(6):479-87.
2011: Hikmat Al-Ahmadie; Gopa Iyer; Manickam Janakiraman; Oscar Lin; Adriana Heguy; SK Tickoo; Samson W Fine; Anuradha Gopalan; Ying-bei Chen; Arjun Balar; Jamie Riches; Bernard Bochner; Guido Dalbagni; Dean F Bajorin; Victor E Reuter; Matthew I Milowsky; David B Solit
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.
The Journal of pathology 2011;224(2):270-9.
2011: David B Solit; Neal Rosen
Resistance to BRAF inhibition in melanomas.
The New England journal of medicine 2011;364(8):772-4.
2011: Poulikos I Poulikakos; David B Solit
Resistance to MEK inhibitors: should we co-target upstream?
Science signaling 2011;4(166):pe16.
2011: Thomas Bachleitner-Hofmann; Mark Y Sun; Chin-Tung Chen; David Liska; Zhaoshi Zeng; Agnes Viale; Adam B Olshen; Martina Mittlboeck; James G Christensen; Neal Rosen; David B Solit; Martin R Weiser
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(1):122-33.
2011: Efsevia Vakiani; David B Solit
KRAS and BRAF: drug targets and predictive biomarkers.
The Journal of pathology 2011;223(2):219-29.
2010: David B Solit; Neal Rosen
Oncogenic RAF: a brief history of time.
Pigment cell & melanoma research 2010;23(6):760-2.
2010: David B Solit; Ingo K Mellinghoff
Tracing cancer networks with phosphoproteomics.
Nature biotechnology 2010;28(10):1028-9.
2010: Diane Lauren Reidy; Efsevia Vakiani; Marwan G Fakih; Muhammad Wasif Saif; Joel Randolph Hecht; Noah Goodman-Davis; Ellen M Hollywood; Jinru Shia; Jonathan Schwartz; Kumari Chandrawansa; Aruna Dontabhaktuni; Hagop Youssoufian; David B Solit; Leonard B Saltz
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(27):4240-6.
2010: Ensar Halilovic; Qing-Bai She; Qing Ye; Raymond Pagliarini; William R Sellers; David B Solit; Neal Rosen
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Cancer research 2010;70(17):6804-14.
2010: Eric W Joseph; Christine A Pratilas; Poulikos I Poulikakos; Madhavi Tadi; Weiqing Wang; Barry S Taylor; Ensar Halilovic; Yogindra Persaud; Feng Xing; Agnes Viale; James Tsai; Paul B Chapman; Gideon Bollag; David B Solit; Neal Rosen
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(33):14903-8.
2010: Manickam Janakiraman; Efsevia Vakiani; Zhaoshi Zeng; Christine A Pratilas; Barry S Taylor; Dhananjay Chitale; Ensar Halilovic; Manda Wilson; Kety Huberman; Julio Cezar Ricarte Filho; Yogindra Persaud; Douglas A Levine; James A Fagin; Suresh C Jhanwar; John M Mariadason; Alex E Lash; Marc Ladanyi; Leonard B Saltz; Adriana Heguy; Philip B Paty; David B Solit
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Cancer research 2010;70(14):5901-11.
2010: Qing-Bai She; Ensar Halilovic; Qing Ye; Wei Zhen; Senji Shirasawa; Takehiko Sasazuki; David B Solit; Neal Rosen
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.
Cancer cell 2010;18(1):39-51.
2010: Christine A Pratilas; David B Solit
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(13):3329-34.
2010: Jonathan R Dry; Sandra Pavey; Christine A Pratilas; Chris Harbron; Sarah Runswick; Darren Hodgson; Christine Chresta; Rose McCormack; Natalie Byrne; Mark Cockerill; Alexander Graham; Garry Beran; Andrew Cassidy; Carolyn Haggerty; Helen Brown; Gillian Ellison; Judy Dering; Barry S Taylor; Mitchell Stark; Vanessa Bonazzi; Sugandha Ravishankar; Leisl Packer; Feng Xing; David B Solit; Richard S Finn; Neal Rosen; Nicholas K Hayward; Tim French; Paul D Smith
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).
Cancer research 2010;70(6):2264-73.
2010: Sarat Chandarlapaty; M Scaltriti; P Angelini; Q Ye; M Guzman; Clifford Hudis; Larry Norton; David B Solit; Joaquín Arribas; José Baselga; Neal Rosen
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
Oncogene 2010;29(3):325-34.
2010: Selvaraju Veeriah; Barry S Taylor; Shasha Meng; Fang Fang; Emrullah Yilmaz; Igor Vivanco; Manickam Janakiraman; Nikolaus Schultz; Aphrothiti J Hanrahan; William Pao; Marc Ladanyi; Chris Sander; Adriana Heguy; Eric C Holland; Philip B Paty; Paul Mischel; Linda Liau; Timothy F Cloughesy; Ingo K Mellinghoff; David B Solit; Timothy Chan
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.
Nature genetics 2010;42(1):77-82.
2009: Aphrothiti J Hanrahan; David B Solit
Lung cancer profiling: Genetic and molecular predictors of MEK-dependence.
Cancer biology & therapy 2009;8(21):2081-3.
2009: Hongbiao Carl Le; Mihaela Lupu; Khushali Kotedia; Neal Rosen; David B Solit; Jason A Koutcher
Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2009;62(5):1112-9.
2009: Kevin Kalinsky; Lindsay M Jacks; Adriana Heguy; Sujata M Patil; Marija Drobnjak; Umeshkumar K Bhanot; Cyrus V Hedvat; Tiffany A Traina; David B Solit; William Gerald; Mary Ellen Moynahan
PIK3CA mutation associates with improved outcome in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5049-59.
2009: Selvaraju Veeriah; Cameron Brennan; Shasha Meng; Bhuvanesh Singh; James A Fagin; David B Solit; Philip B Paty; Dan Rohle; Igor Vivanco; Juliann Chmielecki; William Pao; Marc Ladanyi; William L Gerald; Linda Liau; Timothy C Cloughesy; Paul Mischel; Chris Sander; Barry Taylor; Nikolaus Schultz; John Major; Adriana Heguy; Fang Fang; Ingo K Mellinghoff; Timothy Chan
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(23):9435-40.
2009: Julio C Ricarte-Filho; Mabel M Ryder; Dhananjay A Chitale; Michael Rivera; Adriana Heguy; Marc Ladanyi; Manickam Janakiraman; David B Solit; Jeffrey A Knauf; R Michael Tuttle; Ronald A Ghossein; James A Fagin
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Cancer research 2009;69(11):4885-93.
2009: Michael J Morris; Neeta Pandit-Taskar; Jorge Carrasquillo; Chaitanya R Divgi; Susan F Slovin; W Kevin Kelly; Dana Elizabeth Rathkopf; Gretchen A Gignac; David B Solit; Lawrence H Schwartz; Ryan D Stephenson; Christina Hong; Anthony Delacruz; Tracy Curley; Glenn Heller; Xiaoyu Jia; Joseph A O'Donoghue; Steven M Larson; Howard I Scher
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(15):2436-42.
2009: Christine A Pratilas; Barry S Taylor; Qing Ye; Agnes Viale; Chris Sander; David B Solit; Neal Rosen
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(11):4519-24.
2009: Gregory J Riely; Naiyer A Rizvi; Mark G Kris; Daniel T Milton; David B Solit; Neal Rosen; Emir Senturk; Christopher G Azzoli; Julie R Brahmer; Francis M Sirotnak; Venkatraman E Seshan; Margaret Fogle; Michelle Ginsberg; Vincent A Miller; Charles Rudin
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):264-70.
2008: David B Solit; Iman Osman; David Polsky; Katherine S Panageas; Adil Daud; James S Goydos; Jerrold B Teitcher; Jedd D Wolchok; F Joseph Germino; Susan E Krown; Daniel G Coit; Neal Rosen; Paul B Chapman
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(24):8302-7.
2008: Christine A Pratilas; Aphrothiti J Hanrahan; Ensar Halilovic; Yogindra Persaud; Junichi Soh; Dhananjay Chitale; Hisayuki Shigematsu; Hiromasa Yamamoto; Ayana Sawai; Manickam Janakiraman; Barry S Taylor; William Pao; Shinichi Toyooka; Marc Ladanyi; Adi Gazdar; Neal Rosen; David B Solit
Genetic predictors of MEK dependence in non-small cell lung cancer.
Cancer research 2008;68(22):9375-83.
2008: Thomas Bachleitner-Hofmann; Mark Y Sun; Chin-Tung Chen; Laura H Tang; Lin Song; Zhaoshi Zeng; Manish A Shah; James G Christensen; Neal Rosen; David B Solit; Martin R Weiser
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Molecular cancer therapeutics 2008;7(11):3499-508.
2008: Ensar Halilovic; David B Solit
Therapeutic strategies for inhibiting oncogenic BRAF signaling.
Current opinion in pharmacology 2008;8(4):419-26.
2008: Jenifer L Marks; Yixuan Gong; Dhananjay Chitale; Ben Golas; Michael D McLellan; Yumi Kasai; Li Ding; Elaine R Mardis; Richard K Wilson; David B Solit; Ross Levine; Kathrin Michel; Roman K Thomas; Valerie W Rusch; Marc Ladanyi; William Pao
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
Cancer research 2008;68(14):5524-8.
2008: Rebecca Leboeuf; Jacqueline E Baumgartner; Miriam Benezra; Roberta Malaguarnera; David B Solit; Christine A Pratilas; Neal Rosen; Jeffrey A Knauf; James A Fagin
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
The Journal of clinical endocrinology and metabolism 2008;93(6):2194-201.
2008: Kenneth Pienta; Cory Abate-Shen; David B Agus; Ricardo M Attar; Leland W K Chung; Norman M Greenberg; William C Hahn; John T Isaacs; Nora M Navone; Donna M Peehl; Jonathon W Simons; David B Solit; Howard R Soule; Terry A VanDyke; Michael J Weber; Lily Wu; Robert L Vessella
The current state of preclinical prostate cancer animal models.
The Prostate 2008;68(6):629-39.
2008: Ayana Sawai; Sarat Chandarlapaty; Heidi Greulich; Mithat Gonen; Qing Ye; Carlos L Arteaga; William R Sellers; Neal Rosen; David B Solit
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Cancer research 2008;68(2):589-96.
2008: David B Solit; Gabriela Chiosis
Development and application of Hsp90 inhibitors.
Drug discovery today 2008;13(1-2):38-43.
2008: Erik Henke; Jonathan Perk; Jelena Vider; Paola de-Candia; Yvette Chin; David B Solit; Vladimir Ponomarev; Luca Cartegni; Katia Manova-Todorova; Neal Rosen; Robert Benezra
Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo.
Nature biotechnology 2008;26(1):91-100.
2008: Sarat Chandarlapaty; Ayana Sawai; Qing Ye; Anisa Scott; Melanie Silinski; Ken Huang; Pat Fadden; Jeff Partdrige; Steven Hall; Paul Steed; Larry Norton; Neal Rosen; David B Solit
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):240-8.
2007: David B Solit; Elmer B Santos; Christine A Pratilas; Jose Lobo; Maxim Moroz; Shangde Cai; Ronald Blasberg; Judith Leopold; Steven M Larson; Neal Rosen
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition.
Cancer research 2007;67(23):11463-9.
2007: Shanu Modi; Alison T Stopeck; Michael S Gordon; David Mendelson; David B Solit; Rochelle Bagatell; Weining Ma; Jennifer Wheler; Neal Rosen; Larry Norton; Gillian F Cropp; Robert G Johnson; Alison L Hannah; Clifford Hudis
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5410-7.
2007: Susan F Slovin; Govind Ragupathi; Celina Fernandez; Meghan Diani; Matthew P Jefferson; Andrew Wilton; W Kevin Kelly; Michael J Morris; David B Solit; Henrik Clausen; Philip O Livingston; Howard I Scher
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".
Cancer immunology, immunotherapy : CII 2007;56(12):1921-30.
2007: Christine A Pratilas; David B Solit
Therapeutic strategies for targeting BRAF in human cancer.
Reviews on recent clinical trials 2007;2(2):121-34.
2007: Julie L Eiseman; Jianxia Guo; Ramesh K Ramanathan; Chandra P Belani; David B Solit; Howard I Scher; S Percy Ivy; Eleanor G Zuhowski; Merrill J Egorin
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2121-7.
2007: David B Solit; S Percy Ivy; Catherine Kopil; Rachel Sikorski; Michael J Morris; Susan F Slovin; W Kevin Kelly; Anthony Delacruz; Tracy Curley; Glenn Heller; Steven M Larson; Lawrence H Schwartz; Merrill J Egorin; Neal Rosen; Howard I Scher
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1775-82.
2007: Matthew G Fury; David B Solit; Yungpo Bernard Su; Neal Rosen; Francis M Sirotnak; Robert P Smith; Christopher G Azzoli; Jorge Gomez; Vincent A Miller; Mark G Kris; Barbara A Pizzo; Roxanne Henry; David G Pfister; Naiyer A Rizvi
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2007;59(4):467-75.
2007: David B Solit; Neal Rosen
Targeting HER2 in prostate cancer: where to next?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(3):241-3.
2007: Lucia Regales; Marissa N Balak; Yixuan Gong; Katerina Politi; Ayana Sawai; Carl Le; Jason A Koutcher; David B Solit; Neal Rosen; Maureen F Zakowski; William Pao
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.
PloS one 2007;2(8):e810.
2006: seungchan yang; Shimian Qu; Marianela Perez-Tores; Ayana Sawai; Neal Rosen; David B Solit; Carlos L Arteaga
Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors.
Cancer research 2006;66(14):6990-7.
2006: Gabriela Chiosis; Eloisi Caldas Lopes; David B Solit
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Current opinion in investigational drugs (London, England : 2000) 2006;7(6):534-41.
2006: Peter Smith-Jones; David B Solit; Farzana Afroze; Neal Rosen; Steven M Larson
Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(5):793-6.
2006: Kathryn E O'Reilly; Fredi Rojo; Qing-Bai She; David B Solit; Gordon B Mills; Debra Smith; Heidi Lane; Francesco Hofmann; Daniel J Hicklin; Dale L Ludwig; José Baselga; Neal Rosen
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
Cancer research 2006;66(3):1500-8.
2006: David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Leopold; William R Sellers; Neal Rosen
BRAF mutation predicts sensitivity to MEK inhibition.
Nature 2006;439(7074):358-62.
2006: O M Grbovic; Andrea D Basso; Ayana Sawai; Qing Ye; Paul Friedlander; David B Solit; Neal Rosen
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(1):57-62.
2006: David B Solit; Neal Rosen
Hsp90: a novel target for cancer therapy.
Current topics in medicinal chemistry 2006;6(11):1205-14.
2005: Michael J Morris; Chaitanya R Divgi; Neeta Pandit-Taskar; Maria Batraki; Nyasha Warren; Angelo Nacca; Peter Smith-Jones; Lawrence H Schwartz; W Kevin Kelly; Susan F Slovin; David B Solit; Jennifer Halpern; Anthony Delacruz; Tracy Curley; Ronald Finn; Joseph A O'Donoghue; Philip O Livingston; Steven M Larson; Howard I Scher
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7454-61.
2005: Qing-Bai She; David B Solit; Qing Ye; Kathryn E O'Reilly; Jose Lobo; Neal Rosen
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.
Cancer cell 2005;8(4):287-97.
2005: David B Solit; Yuhong She; Jose Lobo; Mark G Kris; Howard I Scher; Neal Rosen; Francis M Sirotnak
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(5):1983-9.
2005: Robert Benezra; Erik Henke; Alessia Ciarrocchi; Marianna B Ruzinova; David B Solit; Neal Rosen; D Nolan; Vivek Mittal; Paola de-Candia
Induction of complete regressions of oncogene-induced breast tumors in mice.
Cold Spring Harbor symposia on quantitative biology 2005;70():375-81.
2004: Gabriela Chiosis; Maria Vilenchik; Joungnam Kim; David B Solit
Hsp90: the vulnerable chaperone.
Drug discovery today 2004;9(20):881-8.
2004: Zhi-Qiang Yang; Xudong Geng; David B Solit; Christine A Pratilas; Neal Rosen; Samuel J Danishefsky
New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target.
Journal of the American Chemical Society 2004;126(25):7881-9.
2004: Maria Vilenchik; David B Solit; Andrea Basso; Henri Huezo; Brian Lucas; Huazhong He; Neal Rosen; Claudia Spampinato; Paul Modrich; Gabriela Chiosis
Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.
Chemistry & biology 2004;11(6):787-97.
2004: Peter Smith-Jones; David B Solit; Timothy Akhurst; Farzana Afroze; Neal Rosen; Steven M Larson
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.
Nature biotechnology 2004;22(6):701-6.
2004: Michael J Morris; Oren Smaletz; David B Solit; W Kevin Kelly; Susan F Slovin; Carlos D Flombaum; Tracy Curley; Anthony Delacruz; Lawrence H Schwartz; Martin Fleisher; Andrew Zhu; Meghan Diani; Mary Fallon; Howard I Scher
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
Cancer 2004;100(9):1868-75.
2004: Paola de-Candia; Robert Benera; David B Solit
A role for Id proteins in mammary gland physiology and tumorigenesis.
Advances in cancer research 2004;92():81-94.
2004: Peter Smith-Jones; David B Solit
Generation of DOTA-conjugated antibody fragments for radioimmunoimaging.
Methods in enzymology 2004;386():262-75.
2003: Richard M Enmon; Wei-Hong Yang; Ase M Ballangrud; David B Solit; Glenn Heller; Neal Rosen; Howard I Scher; George Sgouros
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.
Cancer research 2003;63(23):8393-9.
2003: David B Solit; Michael J Morris; Susan F Slovin; Tracy Curley; Lawrence H Schwartz; Steven M Larson; Michael W Kattan; Beryl Hartley-Asp; Howard I Scher; W Kevin Kelly
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
Cancer 2003;98(9):1842-8.
2003: Paola de-Candia; David B Solit; Dilip D Giri; Edi Brogi; Peter M Siegel; Adam B Olshen; William J Muller; Neal Rosen; Robert Benezra
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(21):12337-42.
2003: David B Solit; Howard I Scher; Neal Rosen
Hsp90 as a therapeutic target in prostate cancer.
Seminars in oncology 2003;30(5):709-16.
2003: Qing-Bai She; David B Solit; Andrea Basso; Mark M Moasser
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4340-6.
2003: Gabriela Chiosis; Brian Lucas; Henri Huezo; David B Solit; Andrea Basso; Neal Rosen
Development of purine-scaffold small molecule inhibitors of Hsp90.
Current cancer drug targets 2003;3(5):371-6.
2003: Oren Smaletz; Matthew D Galsky; Howard I Scher; Anthony Delacruz; Susan F Slovin; Michael J Morris; David B Solit; U Davar; Lawrence H Schwartz; W Kevin Kelly
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(10):1518-24.
2003: David B Solit; Andrea D Basso; Adam B Olshen; Howard I Scher; Neal Rosen
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
Cancer research 2003;63(9):2139-44.
2003: Kana Yamamoto; Robert M Garbaccio; Shawn J Stachel; David B Solit; Gabriela Chiosis; Neal Rosen; Samuel J Danishefsky
Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol.
Angewandte Chemie (International ed. in English) 2003;42(11):1280-4.
2002: Andrea D Basso; David B Solit; Gabriela Chiosis; Banabihari Giri; Philip Tsichlis; Neal Rosen
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function.
The Journal of biological chemistry 2002;277(42):39858-66.
2002: David B Solit; Fuzhong F Zheng; Marija Drobnjak; Pamela N Münster; Brian Higgins; David Verbel; Glenn Heller; William Tong; Carlos Cordon-Cardo; David B Agus; Howard I Scher; Neal Rosen
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):986-93.
2002: Andrea D Basso; David B Solit; Pamela N Munster; Neal Rosen
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.
Oncogene 2002;21(8):1159-66.
2001: Pamela N Münster; Andrea Basso; David B Solit; Larry Norton; Neal Rosen
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2228-36.
1995: David B Solit; Joel Goldwein
Posterior fossa: analysis of a popular technique for estimating the location in children with medulloblastoma.
Radiology 1995;195(3):697-8.